RMD News: ResMed CEO: Weight-Loss Drugs Aren’t Cutting Demand for Sleep Apnea Treatment - 29th Jan 2024, 4:30pm

[annb0t]

As excitement built last year over weight-loss drugs from Novo Nordisk and Eli Lilly investors abandoned companies that treat disorders inflamed by obesity. Shares of ResMed sank 40% from July to October, on fears that fewer people would suffer from the nighttime breathing problem known as sleep apnea—which ResMed’s devices relieve. ResMed stock has recovered some, but not all, of its losses after reporting a couple quarters of undisturbed growth.

Continue reading

>>> Read more: ResMed CEO: Weight-Loss Drugs Aren’t Cutting Demand for Sleep Apnea Treatment